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Monofunctional platinum(II) complexes, such as phenanthriplatin and
pyriplatin, have notably different characteristics from the bifunctional anticancer
complexes, such as cisplatin and oxaliplatin, which have detrimental toxicities
and resistance associated with them. The unique properties of the
monofunctional complexes may be exploited to target cancer cells without
producing the toxic side effects associated with the current FDA-approved
platinum-based anticancer drugs. To advance the understanding of these
monofunctional platinum(II) complexes, this study replaced the chloride leaving
ligand with an acetate group, which should increase solubility and alter the rate of
reactivity with key amino acid and nucleotide targets. Phenanthriplatin and
pyriplatin compounds were reacted with silver acetate to form insoluble silver
chloride and the desired complex. Proton nuclear magnetic resonance (1H NMR)
spectroscopy was used to characterize the new complexes and conduct kinetic
assays with guanosine 5'-monophosphate (5’-GMP). A rate constant of 2.9 (±
0.7) x 10-2 M-1s-1 was determined for the reaction between pyriplatin and 5’-GMP,
previously. A preliminary rate constant of 1.8 (± 0.1) x 10-2 M-1s-1 was determined
for the newly synthesized cis-[Pt(NH3)2(py)OAc]+ complex with 5’-GMP. Ligand
exchange kinetics directly influences the anticancer activity and toxicity of
platinum drugs. Initial results indicate that the solubility is increased, and the rate
of reaction is decreased by the acetate ligand.

viii

1. INTRODUCTION
1.1 History of Platinum(II) Complexes
Platinum(II)-based anticancer complexes are among the most commonly
used for the treatment of a variety of cancers; such as cervical, colorectal, lung,
ovarian, and testicular cancers.1 The Food and Drug Administration (FDA)approved anticancer complexes cisplatin [cis-diamminedichloroplatinum(II)],
oxaliplatin [(R,R)-1,2-diaminocyclohexane)oxalatoplatinum(II)], and carboplatin
[cis-diammine(1,1′-cyclobutanedicarboxylato)platinum(II)] (Figure 1) are currently
the most effective chemotherapies in clinical use, and are foundational in cancer
treatment.2

Figure 1. FDA-approved bifunctional platinum(II) anticancer complexes.

However, there are some critical problems associated with the use of
these anticancer complexes, including cumulative toxicities of hepatotoxicity
(chemically driven liver damage), nephrotoxicity (toxic effects on renal function),
ototoxicity (toxic effects on the auditory nerve), and neurotoxicity or peripheral
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neuropathy (damage to the peripheral nerves);3 as well as acquired and intrinsic
resistances, which are a consequence of reduced cellular uptake, intracellular
changes, replicative bypass mechanisms, increased repair, and altered apoptotic
pathways.4 Two important research objectives have emerged in order to
circumvent these detrimental effects: devising novel anticancer complexes with
reduced toxicities and resistances, as well as increasing the knowledge of the
mechanisms of action of these novel complexes. Particularly of interest are the
mechanisms of action by which DNA-platination occurs; such as aquation
reactions, anation reactions, biotransformation reactions with biologically relevant
nucleophiles, and degradation reactions.5,6
1.2 Bifunctional Platinum(II) Anticancer Complexes
The cytotoxic action of the bifunctional complexes arises from their
interaction with DNA, and their ability to form thermodynamically stable bidentate
Pt-DNA adducts. Once the complex enters the cell, it is activated through an
aquation reaction, where the leaving ligand is replaced by a molecule of water.
The water molecule is then subsequently replaced in the reaction with DNA,
forming a covalent bond with DNA at the N7 position of guanine, the N1 or N7
position of adenine, or minimally the N3 position of cytosine.7 These platinum(II)
complexes have been found to bind predominantly to the N7 position of guanine,
which is more accessible than the positions on adenine and cytosine.
Furthermore, the N7 position of guanine is the most reactive nucleophilic site on
DNA, which aids the electrophilic assault by a platinum(II) complex. 8
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The aquated form of the platinum complex initially binds covalently to DNA
to form a monodentate adduct, followed by a subsequent reaction to form the
bidentate adduct (Figure 2) in the form of a (GA)-1,2-intrastrand cross-link, (GG)1,2-intrastrand cross-link, or (GC)-interstrand cross-link. The primarily observed
structure was found to be the (GG)-1,2-intrastrand cross-link.9,10 The result of this
adduct formation is the distortion of DNA, upwards of 55 degrees, which leads to
several downstream biological effects, most notable of which is transcription
inhibition and eventually the initiation of apoptotic pathways.11

Figure 2. Cisplatin-DNA primary adduct.
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The process of forming this primary platinum(II)-DNA adduct is controlled
kinetically, rather than thermodynamically. The aquation reaction is the ratedetermining step in the overall reaction. As a result of the elevated concentration
of chloride ions in both the blood and extracellular fluid, the complex remains
neutral in these areas.12 The complex is then passively diffused into the cell or
carried into the cell via mediated active transport, where the aquation of the
complex is promoted as a result of the significantly lower cellular concentration of
chloride ions, thereby activating the complex.12 The activated complex then
proceeds to assault the nucleophilic sites previously mentioned.
However, only a fraction of the platinum compound that is administered
reacts with DNA; the DNA-platination reactions discussed previously (anation,
biotransformation, and degradation) are competing reactions, and therefore, the
majority of the administered drug binds to extracellular and intracellular amino
acids.13 Platinum(II) is thiophilic, rendering the amino acids cysteine and
methionine highly reactive ligands.14 The adducts formed between the platinum
complex and these proteins are considered to be a significant contributor to
platinum resistances and toxicities, given that many of the interactions are
irrevocable.15 Reedijk and coworkers16 studied the role that proteins play in drug
distribution and metabolism. They discovered that these platinum(II) complexes
translocate from the sulfur atom of S-guanosyl-L-homocysteine to the guanine N7
position.16 Moreover, Pinato and colleagues14 characterized the reactivity profile
of four different bifunctional platinum(II) complexes with three distinct proteins, to
identify the physiological significance that these processes have as a transitional
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step in forming the platinum(II)-DNA adducts. They discovered that the reactions
between the studied complexes and the chosen proteins promoted
oligomerization of the proteins, which led them to hypothesize that these
interactions may be connected to platinum(II) anticancer drug nephrotoxicity. 14
Additionally, by examining the platination reactions between DNA and proteins, in
addition to examining platinated proteins as the potential reactive entity, the
researchers determined that a transfer reaction can occur, leading to the DNA
adduct as the final product.14
1.3 Monofunctional Platinum(II) Anticancer Complexes
With the knowledge gained in the studies of bifunctional platinum(II)
complexes, and in response to the complications associated with the current
FDA-approved anticancer drugs, many different strategies have been employed
for the development of novel anticancer drugs and delivery methods to treat
cancer without the detrimental side effects. The development of novel
compounds that have specific selectivity in regard to biologically relevant
nucleophiles with decreased toxicities and resistances has become a
considerably important research objective, and one such response has been the
development of monofunctional platinum(II) compounds. These compounds differ
from the bifunctional compounds in several ways. For instance, they are larger
and more hydrophobic than the bifunctional complexes due to the replacement of
one of the chloride ions with a large N-heterocyclic ammine ligand. This alteration
renders them positively charged, and results in the formation of a monodentate
DNA adduct.
5

Pyriplatin (cis-[Pt(NH3)2(pyridine)Cl]+) and its derivatives (Figure 3) exhibit
an altered spectrum of activity and have noteworthy antitumor properties. 17,18
Lovejoy and coworkers19 conducted experiments that revealed increased
pyriplatin accumulation in cells with increased expression of organic cation
transporters I and II. This led to the conclusion that these transporters mediate
the uptake of pyriplatin, and therefore, that pyriplatin may be used to selectively
target cancerous cells that have organic cation transporter expression while
reducing the toxic side effects in cells that do not express or have less
expression of organic cation transporters.19 The researchers also analyzed
pyriplatin DNA-binding characteristics utilizing x-ray diffraction; it was concluded
that pyriplatin binds to the DNA duplex and forms a monodentate lesion,
predominantly at the guanine N7 position, without distorting the DNA duplex.19

Figure 3. Monofunctional platinum(II) anticancer complexes.
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An x-ray structure of the transcription machinery RNA polymerase II (RNA
Pol II) halted at the pyriplatin-DNA lesion, was provided by Wang et al.18 The
stalled RNA Pol II was discovered to be a result of the use of RNA cytidine
triphosphate (CTP) complemented to the impaired guanine residue.18 This
revealed that that RNA Pol II halts after the incorporation of CTP at the site of
damage, resulting in the rotation of the altered guanine residue into the RNA Pol
II active site, halting transcription beyond the damage site.18 This transcription
inhibition mechanism is significantly different from that of the traditional
bifunctional compounds. Additionally, Zhu and coworkers20 determined that
pyriplatin binds as effectively to DNA, is as efficient at inhibiting transcription, and
is detected and repaired by cellular repair machinery with less efficiency than the
parent compounds. This is an important distinction, owing to the relationship
between the efficacy of anticancer platinum(II) drugs and transcription
inhibition.21
Unfortunately, pyriplatin was found to be more than ten times less
cytotoxic than cisplatin and oxaliplatin. However, due to the distinctive
characteristics discovered for pyriplatin, experiments were conducted by Park
and colleagues1 to improve both the effectiveness and uptake of monofunctional
platinum(II) complexes through the substitution of the pyridine ligand in pyriplatin
with different N-heterocyclic ammine ligands. Utilizing the knowledge of the
mechanism of transcription inhibition discovered by Wang et al.,18 the
researchers formulated the hypothesis that increasing steric bulk of the Nheterocyclic ammine ligand would more effectively hinder the advancement of
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RNA Pol II.1 Two different substitutions, phenanthridine and quinoline for
pyriplatin, yielded two novel complexes named phenanthriplatin (cis[Pt(NH3)2(phenanthridine)Cl]NO3) and quinoplatin (cis[Pt(NH3)2(quinoline)Cl]NO3). The characterization of these compounds led to the
discovery that their coordination geometry is square-planar and that the plane of
the aromatic N-heterocyclic ligand is perpendicular to the platinum coordination
plane. This particular orientation provides protection from an axial nucleophilic
attack perpendicular to the coordination plane; an attack in which the majority of
substitution reactions occur.1 Therefore, it is feasible that this particular
orientation would lead to a reduction in ligand exchange reactions, and thereby
prevent premature deactivation.1
Cytotoxic effects of their newly developed monofunctional platinum(II)
complexes were determined using the MTT assay. The results obtained from
these assays suggested that by increasing the ammine ligand bulk on the
monofunctional compound, the cytotoxicity of the compound would also be
improved; indicating a direct correlation between steric bulk and drug efficacy. 1
Park et al.1 directly compared IC50 values for phenanthriplatin, pyriplatin,
cisplatin, and oxaliplatin in various cell lines. The researchers found
phenanthriplatin to be between four and forty times more cytotoxic than either of
the parent compounds, cisplatin and oxaliplatin.1 Furthermore, IC50 values were
obtained from MTT assays performed seventy-two hours after treatment with the
compounds phenanthriplatin and cisplatin, in both healthy and cancerous lung
fibroblasts.1 These values were used to evaluate the selectivity of cancer cells
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over healthy cells; it was determined that phenanthriplatin exhibited increased
selectivity toward cancerous cells over healthy cells, as indicated by an IC50 ratio
value of 3.9, as opposed to cisplatin’s value of 0.9.1
In an attempt to understand the potent anticancer activity exhibited by
phenanthriplatin, Park et al.1 monitored the platinum distribution within cancer
cells that were treated with a concentration of five micromolar cisplatin,
phenanthriplatin, and pyriplatin, for three hours. They determined that
phenanthriplatin is taken up more effectively by cells than either of the other two
compounds.1 They attributed this to the large hydrophobic ligand,
phenanthridine, which is thought to aid in the transport of the compound across
the cell membrane, thereby increasing its cytotoxicity.1 Further exploration of
transcription inhibition processes by phenanthriplatin was carried out utilizing a
GLuc colorimetric assay. The results demonstrated that in the cancer cell lines
tested, phenanthriplatin inhibited transcription to an equivalent degree as
cisplatin, and that pyriplatin inhibited transcription to a lesser degree than either
cisplatin or phenanthriplatin.1,22,23
1.4 Previous Work and Current Approach
We have recently conducted kinetic assays (Figure 4) with guanosine 5’monophosphate (5’-GMP), a biologically relevant nucleophile, and IC50 statistical
analyses for the parent compound cisplatin, as well as the monofunctional
complexes [Pt(diethylenetriamine)Cl]+ ([Pt(dien)Cl]+), [Pt(N,N-diethyldiethylenetriamine)Cl]+ ([Pt(Et2dien)Cl]+), phenanthriplatin, and pyriplatin in four cancer cell
types (Figure 5). These studies have revealed that the reactions between
9

pyriplatin and phenanthriplatin, individually, with 5’-GMP were over an order of
magnitude slower, relative to cisplatin, and that phenanthriplatin produced IC50
values similar to cisplatin, illustrating strong anticancer activity.24 These results
are comparable to a previous study that determined phenanthriplatin to be 4 – 40
times more cytotoxic than either cisplatin or oxaliplatin in the cells lines tested.1

Figure 4. Monroe and coworkers’24 kinetic assays between 5’-GMP and A. [Pt(dien)Cl]+ (starting
[Pt] of 1 mM). B. [Pt(Et2dien)Cl]+ (starting [Pt] of 18 mM). C. Pyriplatin (starting [Pt] of 5 mM). D.
Phenanthriplatin (starting [Pt] of 5 mM).
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Figure 5. Monroe and coworkers’24 IC50 values for the given complexes in four cancer cell lines.

Due to the unique characteristics of these monofunctional complexes and
the strong anticancer activity displayed by phenanthriplatin, it is an important
research objective to further characterize and elucidate the mechanism of action
of these compounds. This research objective may yield novel complexes that
have reduced toxic side effects and may provide a means to target and treat
specific cancer types that exhibit resistances to the parent compounds. For
instance, the effects of the leaving ligand on the solubility, reactivity, and
cytotoxicity of the current monofunctional complexes is of particular interest. By
exchanging the current leaving ligand for another leaving group, we may analyze
these effects and further characterize these notable complexes.
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2. EXPERIMENTAL
2.1 Materials Used
The following chemicals were purchased from Sigma-Aldrich Chemical
Company: cis-Diamineplatinum(II) dichloride ≥ 99.9% trace metals basis (Product
# 479306, CAS # 15663-27-1); Deuterium oxide, 99.9 atom % D (Product #
151882, CAS # 7789-20-0); Diethyl ether, anhydrous, ACS reagent, ≥ 99.0%,
contains BHT as inhibitor (Product # 673811, CAS # 60-29-7); Dimethyl
sulfoxide-d6, 99.9 atom % D (Product # 151874, CAS # 2206-27-1); Ethyl
alcohol, Pure, 200 proof, anhydrous, ≥ 99.5% (Product # 459836, CAS # 64-175); Methanol, ACS reagent, ≥ 99.8% (Product # 179337, CAS # 67-56-1); Nitric
acid-d solution, 65 wt. % in D2O, 99 atom % D (Product # 176737, CAS # 1358752-5); Phenanthridine, 98% (Product # 157384, CAS # 229-87-8); Silver acetate
ReagentPlus, 99% (Product # 216674, CAS # 563-63-3); Silver nitrate, ACS
reagent, ≥ 99.0% (Product # 209139, CAS # 7761-88-8); Sodium acetate,
ReagentPlus, 99% (Product # 110191, CAS # 127-09-3); Sodium deuteroxide
solution, 40 wt. % in D2O, 99 atom % D (Product # 176788, CAS # 14014-06-3).
Molecular Sieve, Type 4A, 1/16 Beads (Product # MX1583G, CAS # 70955-01-0)
was purchased from Supelco. The subsequent chemicals were purchased from
Acros Organics: N,N-Dimethylformamide, 99+%, extra pure (Product # 11622,
CAS # 68-12-2); Guanosine 5’-monophosphate, disodium salt hydrate, 97%
(Product # 22660, CAS # 5550-12-9); Pyridine, 99+%, extra pure (Product #
13178, CAS # 110-86-1).
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2.2 Synthesis of Platinum(II) Complexes
a) Synthesis of cis-[Pt(NH3)2(py)Cl]+ and cis-[Pt(NH3)2(phen)Cl]+
The syntheses of the parent complexes were carried out according to Park
et al.1 Trace metal basis cis-diamineplatinum(II) dichloride, Cisplatin, (300 mg)
was dissolved in 15 mL of extra pure N,N-Dimethylformamide (DMF). One
equivalent of silver nitrate (169.8 mg) was then added to the Cisplatin solution.
The reaction vessel was subsequently stirred at 55°C, under protection from the
light, for 16 hours. The solution was then syringe filtered, to remove the insoluble
silver chloride, into a round bottom flask. To the filtrate, 0.9 equivalent of the Nheterocyclic ammine ligand was added (pyridine for pyriplatin and phenanthridine
for phenanthriplatin). The reaction vessel was again stirred at 55°C, under
protection from the light, for 16 hours. The solution was then evaporated to
dryness using a rotary evaporator, and the resulting residue was dissolved in 30
mL of methanol, which was then syringe filtered to remove unreacted Cisplatin.
To purify the complex, the methanol solution was stirred intensely, and 100 mL of
diethyl ether was added dropwise in order to precipitate the complex. The
precipitate was then washed twice with 50 mL of diethyl ether each time.
b) Synthesis of cis-[Pt(NH3)2(py)NO3]+
Cis-[Pt(NH3)2(py)Cl]NO3 was dissolved in DI water and one equivalent of
silver nitrate was added. The solution was heated to 55°C, then removed from
the heat and left stirring, under protection from light, for 24 hours. The solution
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was then syringe filtered, to remove the insoluble silver chloride, and was
evaporated to dryness utilizing a rotary evaporator to yield the desired complex.
c) Synthesis of cis-[Pt(NH3)2(py)OAc]+
Cis-[Pt(NH3)2(py)OAc]+ was synthesized by dissolving pyriplatin and one
equivalent of silver acetate, separately, in DI water. Dissolving of the solid was
aided by stirring with a glass stir rod. Once the two solutions were completely
dissolved, they were mixed together in an amber bottle to protect from light, and
a small amount of DI water was used for quantitative transfer of reagents. The
reaction vessel was then placed onto a stir plate, in an incubator set to 55°C, and
left to stir for 24 hours. The solution was then removed from the incubator,
syringe filtered to eliminate the insoluble silver chloride, and allowed to air dry in
a glass mortar. A small amount of pure, anhydrous, ethanol was added to the
mortar, and the residue was grinded with a glass pestle to obtain a working solid.
d) Synthesis of cis-[Pt(NH3)2(phen)OAc]+
Cis-[Pt(NH3)2(phen)OAc]NO3 was synthesized in the same manner as cis[Pt(NH3)2(py)OAc]NO3 stated above. Additionally, cis-[Pt(NH3)2(phen)OAc]OAc
was synthesized per the method stated above, with the addition of one
equivalent of sodium acetate.
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2.3 Sample Preparation
a) pH Adjustment Solutions
All samples were dissolved in D2O for NMR analysis. Solutions used to
adjust pH prior to NMR analysis were 1% and 10% nitric acid-d in deuterium
oxide (D2O) as well as 1% and 10% sodium deuteroxide in D2O. The pH was
observed using an Iq Scientific Iq150 Ph Meter with glass probe.
b) Aquation of cis-[Pt(NH3)2(py)OAc]+
For the aquation kinetic experiments, the complex was dissolved in D2O to
achieve the desired concentration of 5 millimolar (mM). The pH of the solution
was adjusted to 7, and the solution was equilibrated to 25°C in a water bath for
15 minutes prior to the start of the experiment.
c) Conversion of cis-[Pt(NH3)2(py)NO3]+ to cis-[Pt(NH3)2(py)OAc]+
10 mg of cis-[Pt(NH3)2(py)NO3]+ was dissolved in 5 mL D2O. To this
solution, 0.5 equivalent of sodium acetate was added. Another 0.5 equivalent
was added at 24-hour increments until 2.0 equivalents of sodium acetate total
had been added. Following each addition, an NMR spectrum was obtained.
d) Kinetic Experiment between cis-[Pt(NH3)2(py)OAc]+ and 5’-GMP
4.29 mg of cis-[Pt(NH3)2(py)OAc]+ and 4.07 mg of guanosine 5’monophosphate (5’-GMP) were dissolved separately in D2O, to achieve 10 mM
solutions in each. Each solution was then adjusted to a pH of approximately 7.00
with nitric acid-d. The two solutions, plus a vial containing D2O, were placed into
15

a water bath at 25°C for 15 minutes to equilibrate. After the equilibration period,
and moments before starting the kinetics experiment, the solutions were mixed in
the following ratio: 500μL cis-[Pt(NH3)2(py)OAc]+, 400 μL D2O, and 100 μL 5’GMP; resulting in final concentrations of 5 mM cis-[Pt(NH3)2(py)OAc]+ and 1 mM
5’-GMP.
2.4 Nuclear Magnetic Resonance Spectroscopy
A JEOL 500-megahertz (MHz) Nuclear Magnetic Resonance (NMR)
spectrometer and Delta™ NMR Data Processing Software were used for both
the structural analysis of the newly synthesized complexes and the kinetic
assays. All samples were dissolved in D2O and single pulse proton (1H) NMR
spectra were obtained for structural analysis, while a program set to collect a
spectrum every 10 or 15 minutes for a given duration, keeping the NMR at 25°C,
was utilized for the kinetic experiments.
2.5 DynaFit
Biokin, Ltd. DynaFit biochemical program was utilized to perform a nonlinear least squares regression of the chemical kinetics and equilibrium data to
determine the reaction scheme and estimate rate constants. 25
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3. RESULTS
The general reaction scheme for both syntheses is illustrated in Figure 6;
where “Am” is the abbreviation for the ammine ligand and corresponds to either
phenanthridine or pyridine.

Figure 6. Reaction scheme for cis-[Pt(NH3)2(py)OAc]+ and cis-[Pt(NH3)2(phen)OAc]+

The structures of the synthesized complexes, without the counter ion
indicated, are illustrated in Figure 7.

Figure 7. Chemical structures of the newly synthesized complexes.
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3.1 Characterization of cis-[Pt(NH3)2(py)OAc]+
The first complex synthesized was cis-[Pt(NH3)2(py)OAc]+.
Characterization of the complex was carried out utilizing proton NMR
spectroscopy, as described in the experimental section. The first attempt at
analysis yielded the spectrum shown in Figure 8A and Figure 9A; the images
correspond to the signal from the hydrogen atoms on the acetate group and the
aromatic hydrogen signals, respectively.
Potassium acetate was dissolved in D2O and was analyzed to determine
that free acetate in solution presents as a single peak at approximately 1.74 parts
per million (ppm). In comparing the two spectra, focusing only on the acetate
signals, it was inconclusive as to whether or not there was acetate bound to
platinum. However, pyriplatin has one doublet at approximately 8.53 ppm, and
cis-[Pt(NH3)2(py)OAc]+ produced two doublets in this range, indicating some
change in structure.
With the knowledge that pyriplatin undergoes aquation in solution, the cis[Pt(NH3)2(py)OAc]+ sample was left for 24 hours at room temperature before
another spectrum was obtained, in an attempt to illuminate any structural
changes. This second set of spectra are shown in Figures 8B and 9B. As the pH
was altered upon aquation, a second peak in the acetate region was revealed, as
well as another doublet for cis-[Pt(NH3)2(py)H2O]+ in the aromatic region. An
overlay of the two spectra is shown for ease of comparison in Figure 8C and
Figure 9C. Parenthetically, these spectra also illustrate the aquation reaction that
occurs for cis-[Pt(NH3)2(py)OAc]+.
18

Figure 8. Acetate signals from the cis-[Pt(NH3)2(py)OAc]+ sample without pH adjustment.
A. Spectrum obtained at hour zero. B. Spectrum obtained at hour 24. C. Overlay of spectra.
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Figure 9. Aromatic hydrogen signals from the cis-[Pt(NH3)2(py)OAc]+ sample without pH
adjustment. A. Spectrum obtained at hour zero. B. Spectrum obtained at hour 24.
C. Overlay of spectra.
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The appearance of a second acetate signal upon pH change served as
evidence that there was both free acetate and bound acetate present in the
sample. However, to further illustrate that at pH 7.0 the two signals appear
overlapped, and to aid in the determination that the second peak was due to
bound acetate, a new sample was created. This sample was adjusted to a pH of
approximately 7.0 and was analyzed using 1H NMR spectroscopy. After 48 hours
at room temperature the pH was monitored and again adjusted to a pH of
approximately 7.0, then reanalyzed using 1H NMR spectroscopy. These spectra
are provided in Figures 10A-B and 11A-B. Figures 10C and 11C are spectra
overlay for comparison. The shift in ppm observed from the acetate signal was
due to the slight difference in pH at the time of analysis. The decrease in peak
height observed was due to diluting the sample in order to read the pH of the
solution for adjustment.

A noteworthy observation from comparing the two spectra displaying the
aromatic portion, the unadjusted pH sample at 24 hours and the adjusted pH
sample at 48 hours, is that the aquated product was decreased at a pH of 7.0
than that was observed at the lower pH value. One possible explanation for this
observation is that at a higher pH the acetate ion may re-coordinate to the
platinum complex.
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Figure 10. Acetate signals from cis-[Pt(NH3)2(py)OAc]+ sample 2 with pH adjustment. A.
Spectrum obtained at hour zero. B. Spectrum obtained at hour 48. C. Overlay of spectra.
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Figure 11. Aromatic hydrogen signals from cis-[Pt(NH3)2(py)OAc]+ sample 2 with pH adjustment.
A. Spectrum obtained at hour zero. B. Spectrum obtained at hour 48. C. Overlay of spectra.
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Furthermore, cis-[Pt(NH3)2(py)NO3]+ was synthesized, per the method in
the experimental section, and was reacted with sodium acetate incrementally, for
visualization of the ligand exchange. The initial pH of the solution was
approximately 5.3; after each addition of sodium acetate the pH was adjusted to
approximately 5.3 prior to analysis by 1H NMR spectroscopy. This experiment is
shown in Figure 12, which is an overlay of the spectra obtained at different
equivalent levels; the peak at approximately 1.74 corresponds to free acetate,
and the peak at approximately 1.84 corresponds to bound acetate. For the
reactions with 0.5 and 1.0 equivalent of sodium acetate, a near equal amount of
bound and free acetate were present. When the equivalent amount was brought
up to 2.0, excess sodium acetate, the equilibrium was shifted toward the
products in the reaction scheme provided at the top of Figure 12.

Figure 12. Overlay of spectra obtained from the reaction between cis-[Pt(NH3)2(py)NO3]+
and increasing equivalents of sodium acetate, at a pH of approximately 5.3.
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3.2 Kinetic Assays
a) Reaction between cis-[Pt(NH3)2(py)OAc]+ and 5’-GMP
In previous experiments, we determined the rate constant for the reaction
between pyriplatin and 5’-GMP.24 To aid in the determination of the effect that the
leaving ligand has on the reactivity of the complex, kinetic assays between cis[Pt(NH3)2(py)OAc]+ and 5’-GMP were conducted, a preliminary rate constant was
obtained, and the results were compared to that of the parent complex. The
specific conditions of the experiment are detailed in the experimental section.
Figure 13 provides the spectra obtained over the course of the kinetic
experiment. The disappearance of the unreacted 5’-GMP H8 signal at
approximately 8.08 ppm and the appearance of a product signal at approximately
8.87 ppm were monitored utilizing 1H NMR spectroscopy. These peaks were
integrated and fit to two different models in DynaFit (Figure 14). The first model,
Figure 14A, was the model used previously for pyriplatin and was first order in
each reactant; the model corresponds to the reaction scheme illustrated in Figure
15A. With knowledge from previous research on the aquation of platinum(II)
complexes, the second model, Figure 14B, was devised after a less than ideal fit
was observed for the new complex and included a first order aquation step,
illustrated in Figure 15B. A third model that made the aquation step an
equilibrium was also used but resulted in an indiscernible change in rate
constants.
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Figure 13. Aromatic region of the spectra obtained from the kinetic experiment between cis[Pt(NH3)2(py)OAc]+ and 5’-GMP. The indicated resonances are from the H8 on 5’-GMP.
A. Spectrum obtained at zero minutes. B. Spectrum obtained at 90 minutes. C. Spectrum
obtained at 190 minutes. D. Spectrum obtained at 290 minutes. E. Overlay of spectra.
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Figure 13. Continued.
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Figure 14. Concentration versus time plots created from the kinetic experiment
between cis-[Pt(NH3)2(py)OAc]+ and 5’-GMP. A. Pseudo first order kinetic
model. B. First order aquation step plus pseudo first order kinetics.

Figure 15. Reaction schemes for the formation of the Platinum-GMP adduct.
A. First order in each reactant. B. First order aquation step followed by first
order in each reactant.

The following table provides a summary of the rate constants for
comparison. The previously determined rate constant for the parent complex as
well as the rate constants obtained from each DynaFit model for the newly
synthesized complex are provided.
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Table 1. Rate constants from kinetic assays between 5’-GMP and pyriplatin (cis[Pt(NH3)2(py)Cl]+)24 and 5’-GMP and cis-[Pt(NH3)2(py)OAc]+.
Species

Label (Figure 15)

Rate Constant

cis-[Pt(NH3)2(py)Cl]+

N/A

2.9 (± 0.7) x 10-2 M-1s-1

k1

1.8 (± 0.1) x 10-2 M-1s-1

k2

3 (± 1) x 10-4 s-1

k3

3.1 (± 0.7) x 10-2 M-1s-1

cis-[Pt(NH3)2(py)OAc]+

b) Aquation of cis-[Pt(NH3)2(py)OAc]+
A kinetic assay for the aquation of cis-[Pt(NH3)2(py)OAc]+ was carried out
per the method described in the experimental section and closely resembled the
kinetic experiment with 5’-GMP. The appearance of the cis-[Pt(NH3)2(py)H2O]+
doublet at approximately 8.61 ppm and the disappearance of the cis[Pt(NH3)2(py)OAc]+ doublet at approximately 8.54 ppm were monitored using 1H
NMR spectroscopy. The peaks were integrated, and the values were fit to a
model in DynaFit (Figure 17) to determine preliminary forward and reverse rate
constants for the aquation reaction illustrated in Figure 16. The forward rate
constant obtained was 1.02 (± 0.03) x 10-5 s-1 and the reverse rate constant was
1.4 (± 0.2) x 10-2 M-1s-1.

Figure 16. Reaction scheme for the aquation of cis-[Pt(NH3)2(py)OAc]+
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Figure 17. Concentration versus time plot created from the
kinetic experiment for the aquation of cis-[Pt(NH3)2(py)OAc]+.

3.3 Characterization of cis-[Pt(NH3)2(phen)OAc]+
The second complex synthesized was cis-[Pt(NH3)2(phen)OAc]+.
Synthesis was carried out through two different approaches, detailed in the
experimental section. The first approach led to the formation of cis[Pt(NH3)2(phen)OAc]NO3. Characterization of the complex was carried out
utilizing 1H NMR spectroscopy and the analysis of the newly synthesized
complex yielded the spectrum shown in Figure 18A. The figure corresponds to
the signals from the hydrogen atoms on the acetate group, both bound to the
platinum and free. The cis-[Pt(NH3)2(phen)OAc]NO3 sample was left for 48 hours
(Figure 18B) and 72 hours (Figure 18C), at room temperature, before additional
spectra were obtained. Overtime, the peak that corresponds to bound acetate, at
approximately 1.63 ppm, decreased as a result of the complex undergoing
aquation.
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Figure 18. Acetate signals from the cis-[Pt(NH3)2(phen)OAc]+ sample without
pH adjustment. A. Spectrum obtained at hour zero. B. Spectrum obtained at
hour 48. C. Spectrum obtained at hour 72. D. Overlay of spectra.
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Figure 18. Continued.

The second approach to led to the formation of cis[Pt(NH3)2(phen)OAc]OAc. This added approach was utilized in an attempt to
obtain a less hygroscopic solid. Characterization of the complex was again
carried out utilizing 1H NMR. Analysis of the complex yielded the spectrum shown
in Figure 19A. The cis-[Pt(NH3)2(phen)OAc]OAc sample was left for 72 hours
(Figure 19B) at room temperature before an additional spectrum was obtained.
Overtime, a decrease was once more observed for the peak associated with
bound acetate, at approximately 1.65 ppm.
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Figure 19. Acetate signals from the cis-[Pt(NH3)2(phen)OAc]OAc sample without pH adjustment.
A. Spectrum obtained at hour zero. B. Spectrum obtained at hour 72. C. Overlay of spectra.
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4. DISCUSSION
Cis-[Pt(NH3)2(py)OAc]+ was synthesized by a single means and was
characterized utilizing 1H NMR spectroscopy. Cis-[Pt(NH3)2(phen)OAc]+ was
synthesized via two different methods and was also characterized using 1H NMR
spectroscopy. The intention in synthesizing these compounds was to create a
compound that was more soluble in aqueous liquid, to be more compatible with
the human body, in addition to altering the reactivity of the complexes.
Both newly synthesized complexes were more soluble in water; in fact,
both complexes were made hygroscopic by the addition of the acetate group in
place of the chloride. This hygroscopicity made the compounds more challenging
to work with, but nonetheless achieved the solubility goal. It is also the reason
that two different methods were used in synthesizing cis-[Pt(NH3)2(phen)OAc]+,
which was even more hygroscopic than cis-[Pt(NH3)2(py)OAc]+. The second
method of synthesis attempted to not only change the leaving ligand, but to also
change the counter ion, which has been implicated in affecting the solubility of a
metal complex. While the second method did not entirely remove the hygroscopic
nature of the compound, it did seem to decrease it, as a more workable solid was
obtained.
In determining the reactivity of the newly synthesized complex cis[Pt(NH3)2(py)OAc]+, kinetic assays were conducted for both the aquation of the
complex and the reaction of the complex with 5’-GMP. A preliminary rate
constant of 1.8 (± 0.1) x 10-2 M-1s-1 was determined for the newly synthesized cis-
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[Pt(NH3)2(py)OAc]+, under the same conditions for which the rate constant was
obtained for the parent complex, cis-[Pt(NH3)2(py)Cl]+. The rate constant
previously determined for the parent complex with 5’-GMP is
2.9 (± 0.7) x 10-2 M-1s-1. Comparing these two rate constants, initial results
indicate that the rate of reaction is decreased by the acetate ligand.
Furthermore, a second model was used to determine the rate constant for
cis-[Pt(NH3)2(py)OAc]+, which included an aquation step prior to the complex
reacting with 5’-GMP. The first step of the reaction yielded a rate constant of 2.9
(± 1.2) x 10-4 s-1, and the second step of the reaction yielded a rate constant of
3.1 (± 0.7) x 10-2 M-1s-1. A notable observation from this experiment is that the
rate constant for the second step is approximately equal to that of the parent
complex, suggesting one of the following: aquation of the chloride on the parent
complex is not rate-limiting or the displacement of water by guanine is just as fast
as the displacement of chloride. Additionally, the rate of aquation was determined
for cis-[Pt(NH3)2(py)OAc]+; the rate constants were 1.02 (± 0.03) x 10-5 s-1 for the
forward direction and 1.4 (± 0.2) x 10-2 M-1s-1 for the reverse direction.
Ligand exchange kinetics directly influences the anticancer activity and
toxicity of platinum drugs, and therefore, further experiments into the effects that
the leaving ligand has on the reactivity and the toxicity of the complex is
desirable. It would also be useful to obtain an aquation constant for cis[Pt(NH3)2(py)Cl]+, for comparison. Future work should include finishing the kinetic
assays for both complexes, attempting to synthesize complexes with additional
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changes to the leaving ligand, a benzoate group for example, and lastly, to
assess the cytotoxicity of the newly synthesized complexes in different cell lines.
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6. ABBREVIATIONS
Any N-heterocyclic ammine ligand………………………………………………

Am

cis-[Pt(NH3)2(phen)Cl]+……………………………………………… Phenanthriplatin
cis-[Pt(NH3)2(py)Cl]+………………………………………………………… Pyriplatin
Cytidine triphosphate……………………………………………………………… CTP
Guanosine 5’-monophosphate………………………………………………
Hydrogen nuclear magnetic resonance……………………………………

5’-GMP
1H

N,N-Dimethylformamide…………………………………………………………

NMR
DMF

OAc……………………………………………………………………………… Acetate
Parts per million…………………………………………………………………… ppm
Phen…………………………………………………………………… Phenanthridine
[Pt(diethylenetriamine)Cl]+……………………………………………… [Pt(dien)Cl]+
[Pt(N,N-diethyldiethylene-triamine)Cl]+ ……………………………

[Pt(Et2dien)Cl]+

Py………………………………………………………………………………

Pyridine

RNA polymerase II………………………………………………………… RNA Pol II
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